{"id":"un-fractionated-heparin","safety":{"commonSideEffects":[{"rate":"1-10","effect":"Bleeding"},{"rate":"0.5-3","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":"0.5-2","effect":"Thrombosis"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL4650299","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Unfractionated heparin (UFH) is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically increases its ability to inhibit thrombin (Factor IIa) and Factor Xa. This prevents the formation of fibrin clots and the extension of existing thrombi. UFH has a rapid onset of action and is used for acute anticoagulation in various thrombotic conditions.","oneSentence":"Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:22.451Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism)"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation for stroke prevention"},{"name":"Perioperative thromboprophylaxis"},{"name":"Extracorporeal circulation anticoagulation"}]},"trialDetails":[{"nctId":"NCT00262054","phase":"PHASE4","title":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2005-11","conditions":"Coronary Disease, Angina Pectoris","enrollment":4570}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Un-fractionated heparin","genericName":"Un-fractionated heparin","companyName":"Deutsches Herzzentrum Muenchen","companyId":"deutsches-herzzentrum-muenchen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors. Used for Acute venous thromboembolism (deep vein thrombosis and pulmonary embolism), Acute coronary syndrome, Atrial fibrillation for stroke prevention.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}